Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free VTVT Stock Alerts

vTv Therapeutics (VTVT) Financials

vTv Therapeutics logo
$27.52 -0.71 (-2.52%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$27.52 0.00 (0.00%)
As of 10/14/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for vTv Therapeutics

Annual Income Statements for vTv Therapeutics

This table shows vTv Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -36 -27 -72 -16 -7.91 -13 -8.50 -13 -19 -20 -18
Consolidated Net Income / (Loss)		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Net Income / (Loss) Continuing Operations		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Total Pre-Tax Income 		-36 -41 -55 -54 -24 -22 -13 -18 -25 -26 -23
Total Operating Income		 -29 -38 -55 -51 -20 -21 -12 -22 -23 -26 -24
Total Gross Profit		 1.55 0.52 0.63 0.29 12 2.76 6.41 4.01 2.02 0.00 1.02
Total Revenue		 1.55 0.52 0.63 0.29 12 2.76 6.41 4.01 2.02 0.00 1.02
Operating Revenue		 1.55 0.52 0.63 0.29 12 2.76 6.41 4.01 2.02 0.00 1.02
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 30 39 56 51 32 24 18 26 25 26 25
Selling, General & Admin Expense		 12 9.08 9.91 11 9.22 8.54 7.25 12 12 12 14
Research & Development Expense		 19 30 46 40 23 15 11 13 12 14 12
Total Other Income / (Expense), net		 -7.20 -2.97 -0.33 -3.17 -3.82 -0.95 -0.95 4.05 -2.33 -0.46 1.58
Interest Expense		 6.01 1.78 0.40 3.09 3.29 1.83 0.69 0.01 0.02 0.01 0.00
Interest & Investment Income		 -0.07 0.04 0.09 0.12 0.06 0.05 0.01 0.00 0.35 0.47 1.57
Other Income / (Expense), net		 -1.13 -1.23 -0.02 -0.19 -0.59 0.83 -0.27 4.06 -2.67 -0.92 0.01
Income Tax Expense		 0.00 0.00 0.00 0.80 0.20 0.10 0.00 0.12 0.20 0.00 0.10
Net Income / (Loss) Attributable to Noncontrolling Interest		 - -14 -39 -39 -16 -8.89 -4.30 -4.74 -5.91 -5.72 -4.24
Basic Earnings per Share		 - - - ($1.67) ($0.69) ($0.59) ($0.18) ($8.29) ($9.98) ($9.71) ($3.20)
Weighted Average Basic Shares Outstanding		 - 8.28M 9.55M 9.69M 12.45M 0.00 47.14M 1.57M 1.92M 2.08M 5.77M
Diluted Earnings per Share		 - - - ($1.67) ($0.69) ($0.59) ($0.18) ($8.29) ($9.98) ($9.71) ($3.20)
Weighted Average Diluted Shares Outstanding		 - 8.28M 9.55M 9.69M 12.45M 0.00 47.14M 1.57M 1.92M 2.08M 5.77M
Weighted Average Basic & Diluted Shares Outstanding		 - 8.28M 9.55M 9.69M 12.45M 30.29M 0.00 0.00 104.58M 3.01M 3.19M

Quarterly Income Statements for vTv Therapeutics

This table shows vTv Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.65 -3.48 -4.87 -5.18 -4.78 -3.63 -5.09 -6.05 -8.70 24 -13
Consolidated Net Income / (Loss)		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24 -13
Net Income / (Loss) Continuing Operations		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24 -13
Total Pre-Tax Income 		-8.54 -4.44 -5.92 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24 -13
Total Operating Income		 -5.37 -4.71 -5.63 -7.16 -6.51 -4.89 -6.50 -7.72 -11 23 -14
Total Gross Profit		 0.00 - 1.00 0.00 0.00 0.02 0.00 0.00 0.00 37 0.00
Total Revenue		 0.00 - 1.00 0.00 0.00 0.02 0.00 0.00 0.00 37 0.00
Operating Revenue		 0.00 - 1.00 0.00 0.00 0.02 0.00 0.00 0.00 37 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.37 4.71 6.63 7.16 6.51 4.91 6.50 7.72 11 14 14
Selling, General & Admin Expense		 2.54 2.57 3.98 3.72 3.28 2.68 3.67 3.62 3.68 4.60 5.16
Research & Development Expense		 2.82 2.14 2.65 3.44 3.22 2.23 2.83 4.10 7.02 8.98 8.77
Total Other Income / (Expense), net		 -3.17 0.27 -0.29 0.75 0.67 0.46 0.29 0.34 0.35 0.87 0.88
Interest & Investment Income		 0.13 0.09 0.08 0.55 0.50 0.43 0.33 0.28 0.40 0.84 0.81
Other Income / (Expense), net		 -3.30 0.19 -0.37 0.19 0.16 0.03 -0.05 0.07 -0.04 0.03 0.06
Income Tax Expense		 0.00 - 0.10 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.89 -0.96 -1.15 -1.23 -1.06 -0.80 -1.13 -1.33 -1.65 0.00 0.00
Basic Earnings per Share		 ($3.19) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.94 ($1.05)
Weighted Average Basic Shares Outstanding		 2.08M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 12.41M 12.41M
Diluted Earnings per Share		 ($3.19) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.65 ($1.05)
Weighted Average Diluted Shares Outstanding		 2.08M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 14.63M 12.41M
Weighted Average Basic & Diluted Shares Outstanding		 104.58M 3.01M 3.01M 3.01M 3.19M 3.19M 3.19M 3.19M 3.94M 3.94M 3.95M

Annual Cash Flow Statements for vTv Therapeutics

This table details how cash moves in and out of vTv Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 0.30 87 -36 -37 -10 0.09 1.47 7.67 -1.29 -2.68 27
Net Cash From Operating Activities		 -31 -37 -48 -45 -27 -23 -18 -19 -16 -19 -25
Net Cash From Continuing Operating Activities		 -31 -37 -48 -45 -27 -23 -18 -19 -16 -19 -25
Net Income / (Loss) Continuing Operations		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Consolidated Net Income / (Loss)		 -36 -41 -55 -55 -24 -22 -13 -18 -25 -26 -23
Depreciation Expense		 0.86 0.50 0.27 0.20 0.22 0.04 0.09 0.09 0.09 0.09 0.09
Non-Cash Adjustments To Reconcile Net Income		 0.95 1.58 2.69 3.82 -7.13 0.40 -4.48 -2.71 10 2.40 2.75
Changes in Operating Assets and Liabilities, net		 -1.41 2.05 4.04 5.04 2.89 -2.05 -1.19 1.04 -1.38 4.39 -5.44
Net Cash From Investing Activities		 0.16 -0.08 -0.08 -0.03 0.01 0.24 0.00 0.00 -0.02 4.40 0.00
Net Cash From Continuing Investing Activities		 0.16 -0.08 -0.08 -0.03 0.01 0.24 0.00 0.00 -0.02 4.40 0.00
Purchase of Property, Plant & Equipment		 -0.03 -0.10 -0.09 -0.06 -0.01 -0.07 0.00 0.00 -0.02 0.00 0.00
Sale and/or Maturity of Investments		 - - - - - - - 0.00 0.00 4.40 0.00
Net Cash From Financing Activities		 31 124 12 7.50 17 23 19 27 15 12 53
Net Cash From Continuing Financing Activities		 31 124 12 7.50 17 23 19 27 15 12 53
Repayment of Debt		 -0.15 -0.09 -0.71 - -5.39 -11 -5.46 -0.72 -0.81 -0.60 -0.19
Issuance of Debt		 34 19 13 7.50 0.50 0.50 0.50 0.89 0.78 0.57 0.00
Issuance of Common Equity		 - 106 - - 22 33 24 27 0.00 0.00 53
Other Financing Activities, net		 - -1.33 - - - 0.00 0.00 0.05 15 12 0.00
Cash Interest Paid		 0.14 0.08 0.24 2.06 2.28 1.30 0.62 0.01 0.02 0.01 0.00
Cash Income Taxes Paid		 - - - - 1.00 0.10 0.00 0.12 0.20 0.00 0.10

Quarterly Cash Flow Statements for vTv Therapeutics

This table details how cash moves in and out of vTv Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -4.36 1.21 43 -6.73 -3.96 -4.83 -5.69 -5.14 73 9.15 -11
Net Cash From Operating Activities		 -4.83 -2.91 -7.34 -6.73 -6.42 -4.83 -5.69 -5.10 -5.22 9.15 -11
Net Cash From Continuing Operating Activities		 -4.83 -2.91 -7.34 -6.73 -6.42 -4.83 -5.69 -5.10 -5.22 9.15 -11
Net Income / (Loss) Continuing Operations		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24 -13
Consolidated Net Income / (Loss)		 -8.54 -4.44 -6.02 -6.41 -5.84 -4.44 -6.22 -7.38 -10 24 -13
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 3.73 0.22 0.59 0.67 0.69 0.80 0.86 0.86 1.05 -15 19
Changes in Operating Assets and Liabilities, net		 -0.05 1.29 -1.93 -1.01 -1.29 -1.21 -0.34 1.42 4.07 0.50 -17

Annual Balance Sheets for vTv Therapeutics

This table presents vTv Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 92 54 28 8.56 9.27 15 25 33 11 38 90
Total Current Assets		 89 52 20 3.47 2.84 7.22 16 27 11 38 90
Cash & Equivalents		 88 52 12 1.68 1.78 5.75 13 12 9.45 37 89
Prepaid Expenses		 1.11 0.61 0.44 0.67 0.81 0.94 2.05 2.54 1.04 1.19 0.74
Other Current Assets		 - - - 1.12 0.25 0.37 0.10 0.02 0.07 0.18 0.22
Plant, Property, & Equipment, net		 0.62 0.44 0.28 0.07 0.46 0.37 0.28 0.21 0.12 0.03 0.00
Total Noncurrent Assets		 1.72 1.93 7.27 5.02 5.97 7.21 9.58 5.94 0.24 0.13 0.01
Other Noncurrent Operating Assets		 1.72 1.93 2.29 0.04 0.99 0.48 0.40 0.35 0.24 0.13 0.01
Total Liabilities & Shareholders' Equity		 92 54 28 8.56 9.27 15 25 33 11 38 90
Total Liabilities		 7.97 23 48 29 18 11 10 27 30 24 25
Total Current Liabilities		 7.73 11 27 19 13 6.39 8.50 7.71 11 5.20 6.64
Accounts Payable		 7.51 11 14 7.70 7.07 6.12 8.02 7.31 10 5.03 6.56
Other Current Liabilities		 - - - - 0.11 0.16 0.18 0.15 0.17 0.17 0.08
Total Noncurrent Liabilities		 0.25 11 21 10 4.73 4.61 1.75 20 19 19 19
Noncurrent Deferred Revenue		 - - 4.50 1.07 1.03 1.01 0.00 19 19 19 19
Other Noncurrent Operating Liabilities		 0.25 0.43 0.29 0.26 1.09 0.73 0.49 1.02 0.28 0.10 0.15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -78 -91 -151 -83 -49 -80 -9.74 -11 -25 14 64
Total Preferred & Common Equity		 -78 -91 -151 -83 -49 -80 -9.74 -11 -25 12 64
Total Common Equity		 -78 -91 -151 -83 -49 -80 -9.74 -11 -25 12 64
Common Stock		 118 124 128 151 184 210 239 255 256 312 391
Retained Earnings		 -196 -215 -279 -234 -234 -290 -249 -266 -281 -300 -327

Quarterly Balance Sheets for vTv Therapeutics

This table presents vTv Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 15 54 46 43 32 26 99 99 88
Total Current Assets		 10 54 46 43 32 26 99 99 88
Cash & Equivalents		 8.24 52 46 42 31 26 99 98 87
Prepaid Expenses		 1.87 0.57 0.30 1.06 0.74 0.36 0.84 0.52 0.42
Other Current Assets		 0.02 0.07 0.07 0.09 0.12 0.09 0.11 0.20 0.53
Plant, Property, & Equipment, net		 0.14 0.10 0.07 0.05 0.02 0.02 0.01 0.00 0.00
Total Noncurrent Assets		 4.66 0.22 0.19 0.16 0.09 0.06 0.02 0.01 0.00
Other Noncurrent Operating Assets		 0.27 0.22 0.19 0.16 0.09 0.06 0.02 0.01 0.00
Total Liabilities & Shareholders' Equity		 15 54 46 43 32 26 99 99 88
Total Liabilities		 29 28 26 25 23 24 29 8.85 8.96
Total Current Liabilities		 10 8.92 6.99 6.42 4.32 5.30 10 6.88 7.02
Accounts Payable		 9.62 8.73 6.79 6.23 4.19 5.22 9.80 6.82 6.99
Other Current Liabilities		 0.17 0.17 0.18 0.18 0.13 0.08 0.03 0.06 0.03
Total Noncurrent Liabilities		 19 19 19 19 19 19 19 1.97 1.94
Noncurrent Deferred Revenue		 19 19 19 19 19 19 19 1.83 1.83
Other Noncurrent Operating Liabilities		 0.49 0.61 0.37 0.16 0.15 0.08 0.12 0.14 0.11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -25 26 20 18 8.90 2.41 71 90 79
Total Preferred & Common Equity		 -25 21 16 15 7.92 2.76 71 90 79
Total Common Equity		 -25 21 16 15 7.92 2.76 71 90 79
Common Stock		 256 307 308 311 313 314 390 393 394
Retained Earnings		 -281 -286 -291 -296 -305 -311 -320 -303 -316

Annual Metrics And Ratios for vTv Therapeutics

This table displays calculated financial ratios and metrics derived from vTv Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
DEI Shares Outstanding		 0.00 32,812,500.00 32,812,500.00 32,812,500.00 40,746,369.00 59,903,154.00 73,880,351.00 90,036,637.00 104,577,460.00 104,577,460.00 3,189,606.00
DEI Adjusted Shares Outstanding		 0.00 820,313.00 820,313.00 820,313.00 1,018,659.00 1,497,579.00 1,847,009.00 2,250,916.00 2,614,437.00 2,614,437.00 3,189,606.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -33.52 -87.41 -19.68 -7.77 -8.71 -4.60 -5.77 -7.33 -7.75 -5.79
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 58.71% -66.49% 22.16% -54.10% 4,172.85% -77.77% 132.06% -37.56% -49.61% -100.00% 0.00%
EBITDA Growth		 2.29% -60.24% -40.62% 9.11% 61.36% -1.61% 40.25% -50.38% -43.40% -4.85% 8.56%
EBIT Growth		 17.44% -31.14% -39.80% 7.58% 59.87% 1.72% 39.58% -45.23% -43.20% -4.82% 8.53%
NOPAT Growth		 19.36% -31.99% -44.25% 7.88% 60.89% -5.39% 43.27% -82.77% -4.05% -13.14% 5.18%
Net Income Growth		 25.11% -13.87% -34.66% 1.28% 56.37% 8.00% 41.64% -38.50% -41.41% -3.56% 12.56%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 58.68% 14.49% 69.49% -38.50% -41.41% 2.71% 67.04%
Operating Cash Flow Growth		 26.16% -20.04% -30.49% 7.57% 39.73% 14.29% 21.80% -7.27% 17.02% -19.09% -32.63%
Free Cash Flow Firm Growth		 0.00% -927.85% 29.48% 18.05% 23.30% 22.10% 43.68% -60.05% 33.67% 82.97% -1,212.12%
Invested Capital Growth		 0.00% 82.96% -99.84% -85.06% 45.92% 23.20% 16.12% -2.17% -99.23% -138.64% 19.27%
Revenue Q/Q Growth		 0.00% 0.00% -22.87% 203.13% 0.00% 0.00% 29,054.55% -61.47% 0.00% -100.00% 1.70%
EBITDA Q/Q Growth		 0.00% 0.00% -4.19% 2.70% 38.15% -36.77% 41.46% -175.19% 11.43% 6.11% -1.45%
EBIT Q/Q Growth		 0.00% 0.00% -4.28% 0.69% 36.68% -33.30% 40.60% -172.78% 11.39% 6.09% -1.44%
NOPAT Q/Q Growth		 0.00% 0.00% -4.21% 1.06% 38.52% -40.64% 40.95% -148.33% 17.45% 6.03% -0.77%
Net Income Q/Q Growth		 0.00% 0.00% -5.03% -1.64% 0.00% 0.00% 39.87% -166.99% 11.92% 5.97% 0.02%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 32.95% 25.00% -166.99% 11.92% 5.91% 4.76%
Operating Cash Flow Q/Q Growth		 0.00% -5.70% -5.37% 10.26% 1.69% -0.03% 16.91% -27.84% -2.98% 17.21% -8.17%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 22.18% -38.47% 7.34% 39.99% -67.74% -6.71% 59.98% -12.54%
Invested Capital Q/Q Growth		 0.00% 0.00% -24.14% -130.76% 37.53% -3.18% -14.39% -172.76% 2.17% -4.28% 5.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 -1,564.95% -7,484.39% -8,615.62% -17,060.48% -154.29% -705.25% -181.60% -437.35% -1,244.70% 0.00% -2,367.85%
Operating Margin		 -1,865.53% -7,349.13% -8,678.23% -17,416.49% -159.43% -755.86% -184.78% -540.87% -1,116.95% 0.00% -2,377.58%
EBIT Margin		 -1,938.22% -7,586.13% -8,681.70% -17,481.79% -164.19% -725.90% -188.99% -439.58% -1,249.26% 0.00% -2,376.60%
Profit (Net Income) Margin		 -2,330.60% -7,920.42% -8,730.76% -18,779.04% -191.77% -793.70% -199.59% -442.72% -1,242.47% 0.00% -2,232.55%
Tax Burden Percent		 100.00% 100.00% 100.00% 101.49% 100.85% 100.46% 100.00% 100.65% 100.80% 100.00% 100.44%
Interest Burden Percent		 120.24% 104.41% 100.57% 105.85% 115.82% 108.84% 105.61% 100.06% 98.66% 98.26% 93.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 59.45% -359.94% -96.16% -913.60% 119.29% 150.20% 507.31% -186.49% -238.10% 408.59% 1,068.97%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -231.82% -75.37% -75.39% -123.46% -111.94% -225.12% -100.79% -87.45% -85.88% 0.00% -98.08%
Return on Assets (ROA)		 -278.75% -78.69% -75.81% -132.62% -130.74% -246.15% -106.44% -88.08% -85.41% 0.00% -92.14%
Return on Common Equity (ROCE)		 488.41% 9,094.32% 141.63% 18,530.90% 698.92% 678.11% 12,979.31% 881.15% 231.53% 1,138.66% 3,140.74%
Return on Equity Simple (ROE_SIMPLE)		 7.24% 52.72% 60.86% 36.18% 28.78% 44.75% 15.98% 182.04% 233.45% 105.21% -186.12%
Net Operating Profit after Tax (NOPAT)		 -20 -27 -39 -35 -14 -15 -8.30 -15 -16 -18 -17
NOPAT Margin		 -1,305.87% -5,144.39% -6,074.76% -12,191.55% -111.60% -529.10% -129.35% -378.61% -781.86% 0.00% -1,664.31%
Net Nonoperating Expense Percent (NNEP)		 91.61% -54.01% -26.22% -102.87% 135.95% 108.33% -120.13% -16.79% -48.21% -60.68% -25.13%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 150.04% 72.90% -118.36%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 756.42% 1,748.94% 1,562.46% 3,894.50% 74.18% 308.86% 113.05% 308.19% 604.61% 0.00% 1,342.28%
R&D to Revenue		 1,209.10% 5,700.19% 7,215.77% 13,621.99% 185.26% 547.00% 171.73% 332.68% 612.34% 0.00% 1,135.30%
Operating Expenses to Revenue		 1,965.53% 7,449.13% 8,778.23% 17,516.49% 259.43% 855.86% 284.78% 640.87% 1,216.95% 0.00% 2,477.58%
Earnings before Interest and Taxes (EBIT)		 -30 -39 -55 -51 -20 -20 -12 -18 -25 -26 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -39 -55 -50 -19 -19 -12 -18 -25 -26 -24
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.61
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.61
Price to Revenue (P/Rev)		 0.00 430.55 249.98 677.67 8.68 36.84 21.42 22.37 34.35 0.00 43.31
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 572.22 379.42 1,147.18 14.64 52.07 32.57 23.03 33.90 0.00 9.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.60 0.00 0.35 -1.00 -0.77 -0.70 0.02 0.02 0.04 -0.01 0.00
Long-Term Debt to Equity		 -0.59 0.00 0.35 -0.78 -0.31 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.57 -2.34 -1.12 -3.12 -0.37 -0.46 1.49 -1.61 -1.83 2.10 10.83
Leverage Ratio		 -0.21 4.57 1.27 6.89 -0.91 -0.61 -4.77 2.12 2.79 -3.48 -11.60
Compound Leverage Factor		 -0.26 4.78 1.28 7.29 -1.06 -0.66 -5.03 2.12 2.75 -3.42 -10.85
Debt to Total Capital		 -147.32% 0.00% 25.94% -97,935.00% -337.33% -231.33% 2.17% 1.65% 3.69% -1.04% 0.00%
Short-Term Debt to Total Capital		 -0.63% 0.00% 0.00% -21,355.00% -201.44% -231.33% 2.17% 1.65% 3.69% -1.04% 0.00%
Long-Term Debt to Total Capital		 -146.69% 0.00% 25.94% -76,580.00% -135.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -1,784.39% 193.31% 287.41% -657,200.00% -1,341.39% -1,506.11% 2,163.92% 161.27% 273.45% -33.40% 14.70%
Common Equity to Total Capital		 2,031.71% -93.70% -214.12% 756,880.00% 1,778.72% 1,837.44% -2,066.08% -62.93% -177.14% 134.44% 85.30%
Debt to EBITDA		 -1.49 0.00 -0.20 -0.39 -0.82 -0.32 -0.01 -0.01 -0.01 -0.01 0.00
Net Debt to EBITDA		 -1.43 0.00 0.74 -0.10 -0.60 -0.10 1.06 1.27 0.70 0.35 0.00
Long-Term Debt to EBITDA		 -1.49 0.00 -0.20 -0.31 -0.33 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.79 0.00 -0.29 -0.55 -1.13 -0.42 -0.01 -0.02 -0.01 -0.01 0.00
Net Debt to NOPAT		 -1.71 0.00 1.05 -0.15 -0.83 -0.13 1.49 1.47 1.11 0.52 0.00
Long-Term Debt to NOPAT		 -1.78 0.00 -0.29 -0.43 -0.46 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 13.48 -3.81 -17.79 -44.59 -40.12 -22.16 -10.22 -11.41 -43.01 -10.89
Noncontrolling Interest Sharing Ratio		 -721.49% 2,626.62% 247.29% 2,128.34% -485.89% -351.46% -2,458.45% 572.48% 197.24% -178.68% -193.81%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.23 11.54 4.56 0.76 0.18 0.21 1.13 1.84 3.52 1.00 7.34
Quick Ratio		 0.20 11.40 4.50 0.73 0.09 0.13 0.92 1.59 3.18 0.90 7.08
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5.84 -48 -34 -28 -21 -17 -9.40 -15 -9.98 -1.70 -22
Operating Cash Flow to CapEx		 0.00% -46,767.09% -58,083.13% -178,240.00% 0.00% 0.00% 0.00% 0.00% -76,295.24% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.97 -27.22 -85.63 -9.03 -6.51 -9.13 -13.58 -1,253.28 -665.00 -130.65 0.00
Operating Cash Flow to Interest Expense		 -5.12 -20.81 -121.13 -14.41 -8.16 -12.60 -26.01 -1,609.00 -1,068.13 -1,467.77 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -5.07 -20.86 -121.34 -14.42 -8.16 -12.47 -26.01 -1,609.00 -1,069.53 -1,467.77 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.01 0.01 0.01 0.68 0.31 0.53 0.20 0.07 0.00 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 78.70 37.26 17.55 0.00 12.40
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.41 0.24 1.19 0.80 70.45 10.41 15.49 12.42 8.32 0.00 14.03
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 4.64 9.80 20.80 0.00 29.43
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 4.64 9.80 20.80 0.00 29.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -26 -4.44 -8.88 -16 -8.89 -6.82 -5.72 -5.85 -12 -28 -22
Invested Capital Turnover		 -0.12 -0.03 -0.10 -0.02 -0.98 -0.35 -1.02 -0.69 -0.23 0.00 -0.04
Increase / (Decrease) in Invested Capital		 -26 22 -4.44 -7.55 7.54 2.06 1.10 -0.12 -5.80 -16 5.36
Enterprise Value (EV)		 0.00 297 241 334 182 144 209 92 68 27 9.40
Market Capitalization		 0.00 223 158 197 108 102 137 90 69 30 44
Book Value per Share		 $0.00 ($2.39) ($2.78) ($4.61) ($2.03) ($0.82) ($1.08) ($0.11) ($0.10) ($0.24) $3.82
Tangible Book Value per Share		 $0.00 ($2.39) ($2.78) ($4.61) ($2.03) ($0.82) ($1.08) ($0.11) ($0.10) ($0.24) $3.82
Total Capital		 -25 84 43 -0.02 -4.66 -2.67 3.88 15 6.06 -18 14
Total Debt		 36 0.00 11 20 16 6.17 0.08 0.26 0.22 0.19 0.00
Total Long-Term Debt		 36 0.00 11 15 6.33 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 35 -88 -40 5.19 12 1.92 -12 -22 -17 -9.26 -37
Capital Expenditures (CapEx)		 -0.30 0.08 0.08 0.03 -0.01 -0.24 0.00 0.00 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.61 -6.54 -11 -14 -7.66 -6.15 -4.84 -6.04 7.48 -9.22 -3.83
Debt-free Net Working Capital (DFNWC)		 -5.10 81 41 -2.30 -5.98 -4.37 0.91 7.38 20 0.23 33
Net Working Capital (NWC)		 -5.25 81 41 -6.57 -15 -11 0.83 7.12 19 0.04 33
Net Nonoperating Expense (NNE)		 16 14 17 19 9.97 7.31 4.51 2.57 9.30 8.11 5.78
Net Nonoperating Obligations (NNO)		 35 -88 -40 3.18 11 2.02 -9.52 -21 -17 -9.26 -37
Total Depreciation and Amortization (D&A)		 5.78 0.53 0.42 1.23 1.23 0.57 0.47 0.09 0.09 0.09 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -426.86% -1,260.69% -1,706.94% -4,885.22% -61.64% -222.43% -75.43% -150.71% 370.86% 0.00% -376.50%
Debt-free Net Working Capital to Revenue		 -329.12% 15,695.57% 6,416.88% -789.00% -48.10% -158.14% 14.17% 184.24% 971.75% 0.00% 3,236.68%
Net Working Capital to Revenue		 -339.12% 15,695.57% 6,416.88% -2,256.70% -123.56% -381.44% 12.86% 177.85% 960.65% 0.00% 3,236.68%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($27.60) ($23.60) ($7.20) ($8.40) ($10.40) ($9.71) ($3.20)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 820.31K 820.31K 820.31K 1.15M 1.63M 2.02M 2.25M 1.87M 2.08M 5.77M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($27.60) ($23.60) ($7.20) ($8.40) ($10.40) ($9.71) ($3.20)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 820.31K 820.31K 820.31K 1.15M 1.63M 2.02M 2.25M 1.87M 2.08M 5.77M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($27.60) ($23.60) ($7.20) ($8.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 820.31K 820.31K 820.31K 311.23K 757.30K 1.18M 1.52M 2.61M 3.01M 3.19M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -27 -39 -35 -14 -15 -8.30 -15 -16 -18 -17
Normalized NOPAT Margin		 -1,305.87% -5,144.39% -6,074.76% -12,191.55% -111.60% -529.10% -129.35% -378.61% -781.86% 0.00% -1,664.31%
Pre Tax Income Margin		 -2,330.60% -7,920.42% -8,730.76% -18,504.12% -190.16% -790.09% -199.59% -439.85% -1,232.56% 0.00% -2,222.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.99 -22.18 -138.30 -16.45 -6.21 -10.98 -17.52 -1,467.08 -1,680.67 -2,032.69 0.00
NOPAT to Interest Expense		 -3.36 -15.04 -96.77 -11.47 -4.22 -8.00 -11.99 -1,263.62 -1,051.87 -1,373.18 0.00
EBIT Less CapEx to Interest Expense		 -4.94 -22.23 -138.51 -16.46 -6.20 -10.85 -17.52 -1,467.08 -1,682.07 -2,032.69 0.00
NOPAT Less CapEx to Interest Expense		 -3.31 -15.09 -96.98 -11.48 -4.22 -7.87 -11.99 -1,263.62 -1,053.27 -1,373.18 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -6.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for vTv Therapeutics

This table displays calculated financial ratios and metrics derived from vTv Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 104,577,460.00 104,577,460.00 3,010,206.00 3,010,206.00 3,010,206.00 3,189,606.00 3,189,606.00 3,194,564.00 3,194,564.00 3,938,259.00 3,938,895.00
DEI Adjusted Shares Outstanding		 2,614,437.00 2,614,437.00 3,010,206.00 3,010,206.00 3,010,206.00 3,189,606.00 3,189,606.00 3,194,564.00 3,194,564.00 3,938,259.00 3,938,895.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.55 -1.33 -1.62 -1.72 -1.59 -1.14 -1.60 -1.89 -2.72 6.13 -3.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -54.76% 27.59% -2.12% 5.45% 26.87% -7.67% -9.42% -10.28% -69.84% 456.28% -81.19%
EBIT Growth		 -54.49% 27.49% -2.11% 5.43% 26.80% -7.61% -9.17% -9.95% -69.28% 455.77% -81.14%
NOPAT Growth		 5.64% 25.79% 24.24% 10.56% -21.20% -3.93% -15.57% -7.91% -64.45% 611.04% -80.42%
Net Income Growth		 -56.18% 27.08% -4.24% 11.12% 31.62% 0.09% -3.29% -15.15% -77.14% 488.19% -76.88%
EPS Growth		 -56.18% 32.39% 45.83% 69.89% 72.41% 62.28% 34.19% -13.58% -22.73% 314.29% -14.13%
Operating Cash Flow Growth		 45.24% 57.65% -41.99% -9.11% -32.77% -65.58% 22.47% 24.28% 18.64% 260.96% -124.59%
Free Cash Flow Firm Growth		 90.11% 843.44% -131.46% -217.75% -168.75% -168.31% -209.34% -0.39% 53.51% 206.58% -262.02%
Invested Capital Growth		 -123.87% -138.64% -4.54% 7.18% 11.27% 19.27% 15.63% 6.27% -16.80% 63.33% 65.94%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 -17.80% 47.96% -32.83% -16.11% 8.89% 23.38% -34.99% -17.02% -40.32% 0.00% -159.51%
EBIT Q/Q Growth		 -17.73% 47.83% -32.64% -16.07% 8.88% 23.30% -34.57% -16.91% -40.29% 0.00% -159.52%
NOPAT Q/Q Growth		 32.90% 12.31% -19.55% -27.15% 9.07% 24.81% -32.93% -18.73% -38.57% 0.00% -141.92%
Net Income Q/Q Growth		 -18.43% 48.00% -35.53% -6.48% 8.88% 24.02% -40.12% -18.71% -40.18% 0.00% -154.09%
EPS Q/Q Growth		 -18.43% 47.65% 29.94% 30.77% -8.64% 28.41% -22.22% -19.48% -17.39% 0.00% -163.64%
Operating Cash Flow Q/Q Growth		 21.62% 39.72% -151.72% 8.26% 4.62% 24.82% -17.87% 10.41% -2.49% 0.00% -225.01%
Free Cash Flow Firm Q/Q Growth		 86.30% 16.94% -121.77% -148.29% -8.77% -16.19% 1.43% 19.42% 49.63% 0.00% -373.70%
Invested Capital Q/Q Growth		 1.36% -4.28% 5.52% 4.49% 5.70% 5.13% 1.26% -6.11% -17.50% 0.00% 1.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% -597.60% 0.00% 0.00% -28,494.12% 0.00% 0.00% 0.00% 63.24% 0.00%
Operating Margin		 0.00% 0.00% -562.70% 0.00% 0.00% -28,776.47% 0.00% 0.00% 0.00% 63.15% 0.00%
EBIT Margin		 0.00% 0.00% -599.80% 0.00% 0.00% -28,623.53% 0.00% 0.00% 0.00% 63.24% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -601.90% 0.00% 0.00% -26,100.00% 0.00% 0.00% 0.00% 65.51% 0.00%
Tax Burden Percent		 100.00% 100.00% 101.69% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.53% 98.21% 98.68% 92.06% 92.06% 91.18% 94.95% 96.41% 96.33% 103.60% 94.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 803.58% 408.59% -198.61% -362.13% -1,335.04% 1,068.97% -131.31% -209.04% -64.17% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -14.45% 0.00% 0.00% -1,181.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -14.50% 0.00% 0.00% -1,077.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 4,887.42% 1,138.66% -12.07% 227.30% 4,012.57% 3,140.74% -108.09% -176.05% -62.06% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 109.44% 0.00% -126.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.76 -3.29 -3.94 -5.01 -4.55 -3.42 -4.55 -5.40 -7.49 23 -9.75
NOPAT Margin		 0.00% 0.00% -393.89% 0.00% 0.00% -20,143.53% 0.00% 0.00% 0.00% 63.15% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -30.17% -8.57% -5.35% -4.23% -4.79% -4.40% -4.00% -5.53% -4.09% 1.35% -5.87%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.45% -15.16% -24.51% -25.42% -23.95% -51.16% -224.73% -10.57% 25.86% -12.40%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 397.80% 0.00% 0.00% 15,735.29% 0.00% 0.00% 0.00% 12.48% 0.00%
R&D to Revenue		 0.00% 0.00% 264.90% 0.00% 0.00% 13,141.18% 0.00% 0.00% 0.00% 24.37% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 662.70% 0.00% 0.00% 28,876.47% 0.00% 0.00% 0.00% 36.85% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.67 -4.52 -6.00 -6.96 -6.34 -4.87 -6.55 -7.66 -11 23 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.65 -4.50 -5.98 -6.94 -6.32 -4.84 -6.54 -7.65 -11 23 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.41 3.23 2.72 3.61 6.98 17.35 1.06 1.74 1.89
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.41 3.23 2.72 3.61 6.98 17.35 1.06 1.74 1.89
Price to Revenue (P/Rev)		 5,554.23 0.00 70.83 53.16 40.83 43.31 3,249.65 2,818.73 4,387.83 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5,395.34 0.00 23.77 11.60 2.17 9.24 1,480.12 1,272.91 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.03 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 4.61 2.10 -2.95 -4.71 -15.79 10.83 -2.39 -3.13 -1.58 -1.31 -1.39
Leverage Ratio		 -7.34 -3.48 3.15 4.91 17.07 -11.60 2.47 3.19 1.61 1.32 1.41
Compound Leverage Factor		 -7.23 -3.42 3.10 4.52 15.72 -10.58 2.35 3.08 1.55 1.37 1.32
Debt to Total Capital		 -3.37% -1.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00% 0.00%
Short-Term Debt to Total Capital		 -3.37% -1.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -76.38% -33.40% 19.98% 19.39% 16.22% 14.70% 10.98% -14.84% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 179.75% 134.44% 80.02% 80.61% 83.78% 85.30% 89.02% 114.84% 99.54% 100.00% 100.00%
Debt to EBITDA		 -0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00
Net Debt to EBITDA		 0.43 0.35 0.00 0.00 0.00 0.00 0.00 0.00 3.30 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00 0.00
Net Debt to NOPAT		 0.64 0.52 0.00 0.00 0.00 0.00 0.00 0.00 4.70 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -27.29 -36.45 -5.24 -7.01 -8.08 -9.22 -11.53 -15.26 -2.23 8.19 5.47
Noncontrolling Interest Sharing Ratio		 -508.21% -178.68% 93.92% 162.77% 400.56% -193.81% 17.68% 15.78% 3.28% 0.99% -0.44%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.99 1.00 6.04 6.61 6.69 7.34 7.39 4.98 9.79 14.36 12.48
Quick Ratio		 0.80 0.90 5.97 6.56 6.51 7.08 7.20 4.90 9.69 14.25 12.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 11 13 -2.80 -6.95 -7.56 -8.78 -8.66 -6.98 -3.51 9.23 -25
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 2,748.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -702.86 0.00 0.00
Operating Cash Flow to Interest Expense		 -1,208.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,044.40 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,208.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,044.40 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.02 0.03 0.03 0.04 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 12.40 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.05 0.00 7.14 8.55 10.53 14.03 0.30 0.39 0.53 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 29.43 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 29.43 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -27 -28 -26 -25 -24 -22 -22 -24 -28 -8.13 -8.01
Invested Capital Turnover		 0.00 0.00 -0.04 -0.04 -0.04 -0.04 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -15 -16 -1.14 1.94 3.01 5.36 4.11 1.57 -3.98 14 16
Enterprise Value (EV)		 49 27 24 12 2.17 9.40 25 22 -24 58 62
Market Capitalization		 50 30 71 53 41 44 55 48 75 156 148
Book Value per Share		 ($0.24) ($0.24) $6.91 $5.47 $4.99 $3.82 $2.48 $0.86 $22.08 $7.25 $19.96
Tangible Book Value per Share		 ($0.24) ($0.24) $6.91 $5.47 $4.99 $3.82 $2.48 $0.86 $22.08 $7.25 $19.96
Total Capital		 -14 -18 26 20 18 14 8.90 2.41 71 90 79
Total Debt		 0.47 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.33 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -9.26 -52 -46 -42 -37 -31 -26 -98 -98 -87
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.92 -9.22 -7.30 -6.31 -5.04 -3.83 -3.46 -4.84 -8.88 -6.16 -6.07
Debt-free Net Working Capital (DFNWC)		 0.32 0.23 45 39 37 33 28 21 90 92 81
Net Working Capital (NWC)		 -0.15 0.04 45 39 37 33 28 21 89 92 81
Net Nonoperating Expense (NNE)		 4.78 1.15 2.08 1.40 1.29 1.01 1.66 1.98 2.86 -0.87 3.30
Net Nonoperating Obligations (NNO)		 -12 -9.26 -52 -46 -42 -37 -31 -26 -98 -98 -87
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -87,944.44% 0.00% -730.40% -631.10% -503.70% -376.50% -20,347.06% -28,488.24% -52,252.94% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 3,588.89% 0.00% 4,495.10% 3,921.50% 3,653.40% 3,236.68% 162,352.94% 123,994.12% 527,182.35% 0.00% 0.00%
Net Working Capital to Revenue		 -1,666.67% 0.00% 4,495.10% 3,921.50% 3,653.40% 3,236.68% 162,352.94% 123,994.12% 525,252.94% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.20) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.94 ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 2.04M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 12.41M 12.41M
Adjusted Diluted Earnings per Share		 ($3.20) ($1.67) ($1.17) ($0.81) ($0.88) ($0.63) ($0.77) ($0.92) ($1.08) $1.65 ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 2.04M 2.08M 4.14M 6.40M 5.46M 5.77M 6.58M 6.59M 8.06M 14.63M 12.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.67) $0.00 $0.00 $0.00 ($0.63) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.61M 3.01M 3.01M 3.01M 3.19M 3.19M 3.19M 3.19M 3.94M 3.94M 3.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.76 -3.29 -3.94 -5.01 -4.55 -3.42 -4.55 -5.40 -7.49 16 -9.75
Normalized NOPAT Margin		 0.00% 0.00% -393.89% 0.00% 0.00% -20,143.53% 0.00% 0.00% 0.00% 44.20% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -591.90% 0.00% 0.00% -26,100.00% 0.00% 0.00% 0.00% 65.51% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2,166.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,147.80 0.00 0.00
NOPAT to Interest Expense		 -939.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,497.86 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2,166.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,147.80 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -939.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,497.86 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

vTv Therapeutics’ financial profile remains dependent on clinical and licensing progress rather than recurring product revenue. The company reported no revenue in Q2 2026, following $36.8 million of revenue in Q1 2026. This caused operating income to swing from a $23.3 million profit in Q1 to a $13.9 million loss in Q2. The Q2 net loss was $13.1 million, or $1.05 per diluted share, compared with net income of $24.1 million, or $1.05 per diluted share, in Q1.

The company continues to spend heavily on development. Q2 research and development expense was $8.8 million, while selling, general and administrative expense was $5.2 million. Total operating expenses of $13.9 million were approximately 29% higher than in Q2 2025, reflecting increased investment in the business and pipeline.

Liquidity is currently the strongest aspect of the balance sheet. Cash and equivalents totaled $86.6 million at June 30, 2026, down from $98.1 million at March 31 and $98.5 million at September 30, 2025. The company had $87.6 million of current assets and $7.0 million of current liabilities, implying substantial short-term liquidity and no reported short-term debt in the latest quarter. However, Q2 operating cash flow was negative $11.4 million, so continued operating losses could reduce this cushion over time.

The balance sheet has improved substantially from 2023 and early 2024, when cash was below $10 million and total equity was negative in Q3 2023. That improvement was supported in part by equity financing, including approximately $77.5 million of common-stock issuance in Q3 2025 and $50.3 million in Q1 2024. These financings strengthened liquidity but also increased the potential for shareholder dilution.

  • Solid liquidity: Q2 2026 cash of $86.6 million was more than 12 times current liabilities, providing a meaningful near-term financial cushion.
  • Low balance-sheet leverage: Total liabilities were $9.0 million versus $78.6 million of common equity, and the latest balance sheet reported no short-term debt.
  • Long-term balance-sheet recovery: Total assets increased from $14.9 million in Q3 2023 to $87.6 million in Q2 2026, while equity moved from negative $25.2 million to positive $78.6 million.
  • Potential funding runway: Although cash declined during Q2, the company’s cash balance remains significant relative to its quarterly operating expenses and current liabilities.
  • Revenue is inconsistent: The $36.8 million recorded in Q1 2026 produced a large quarterly profit, but revenue fell back to zero in Q2, suggesting that results may be driven by milestone, licensing or other nonrecurring activity rather than a stable commercial base.
  • Interest income is supportive but limited: Q2 interest and investment income was $812,000, helping offset a portion of operating expenses but not replacing operating revenue.
  • Cash-flow quality requires monitoring: Q1 operating cash flow was positive $9.2 million, but Q2 operating cash flow was negative $11.4 million and included $18.5 million of noncash adjustments and a $16.9 million use of operating capital.
  • Persistent underlying losses: Excluding the unusual Q1 revenue contribution, vTv has generally reported operating and net losses across the provided periods, including a $13.1 million net loss in Q2 2026.
  • Cash burn is accelerating versus the prior-year quarter: Q2 2026 operating cash outflow of $11.4 million was more than double the $5.1 million outflow reported in Q2 2025.
  • Shareholder dilution risk: Recent equity offerings materially strengthened the balance sheet, but they also increased the common-stock base and may require additional financing if operating cash burn continues.

Overall, vTv Therapeutics has a substantially stronger liquidity position than it had in 2023 and early 2024, but the latest quarter shows the company is still loss-making and cash-flow negative when milestone-related revenue is absent. Investors should focus on whether future revenue becomes repeatable, whether research spending produces clinical or commercial progress, and how long the current cash balance can support operations without further equity issuance.

10/15/26 08:46 AM ETAI Generated. May Contain Errors.

vTv Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, vTv Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

vTv Therapeutics' net income appears to be on an upward trend, with a most recent value of -$22.71 million in 2024, rising from -$36.10 million in 2014. The previous period was -$25.97 million in 2023. View vTv Therapeutics' forecast to see where analysts expect vTv Therapeutics to go next.

vTv Therapeutics' total operating income in 2024 was -$24.18 million, based on the following breakdown:
  • Total Gross Profit: $1.02 million
  • Total Operating Expenses: $25.20 million

Over the last 10 years, vTv Therapeutics' total revenue changed from $1.55 million in 2014 to $1.02 million in 2024, a change of -34.3%.

In the past 11 quarters, vTv Therapeutics' cash and equivalents has ranged from $8.24 million in Q3 2023 to $98.50 million in Q3 2025, and is currently $86.64 million as of their latest financial filing in Q2 2026.

vTv Therapeutics had total debt of $0.00 at the end of 2024, a 100.0% decrease from 2023, and a 100.0% decrease since 2014.

Over the last 10 years, vTv Therapeutics' book value per share changed from 0.00 in 2014 to 3.82 in 2024, a change of 382.5%.


Related Companies

Financial statements for NASDAQ:VTVT last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel